Testing effectiveness (Phase 2)Ended earlyNCT03983395What this trial is testingStudy of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast CancerWho this might be right forBreast Cancer Ichnos Sciences SA 1
Large-scale testing (Phase 3)UnknownNCT05346861What this trial is testingPyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and TrastuzumabWho this might be right forHER2-positive Breast CancerMetastatic Breast Cancer Fudan University 240
Testing effectiveness (Phase 2)Looking for participantsNCT07708194What this trial is testingEntinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab FailureWho this might be right forBreast CancerHER2-positive Breast CancerHormone Receptor-Positive Breast Cancer+1 more Tianjin Medical University Cancer Institute and Hospital 94
Early research (Phase 1)Study completedNCT03685331What this trial is testingHOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast CancerWho this might be right forMetastatic Breast CancerLocally Advanced Breast CancerAdvanced Breast Cancer+2 more Abramson Cancer Center at Penn Medicine 9
Large-scale testing (Phase 3)UnknownNCT02973737What this trial is testingPyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast CancerWho this might be right forHER2 Positive Metastatic Breast Cancer Jiangsu HengRui Medicine Co., Ltd. 279
Large-scale testing (Phase 3)Looking for participantsNCT05950945What this trial is testingTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast CancerWho this might be right forBreast Cancer Daiichi Sankyo 250
Testing effectiveness (Phase 2)WithdrawnNCT01361945What this trial is testingAUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast CancerWho this might be right forBreast CancerMetastatic Breast CancerHER-2 Positive Breast Cancer+1 more Texas Tech University Health Sciences Center, El Paso
Early research (Phase 1)Ended earlyNCT02571530What this trial is testingSuper-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast CancerWho this might be right forNeoplasm Metastasis Northwell Health 2
Testing effectiveness (Phase 2)Active Not RecruitingNCT03379428What this trial is testingTrial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast CancerWho this might be right forBreast NeoplasmsMalignant Neoplasm of Breast US Oncology Research 34
Large-scale testing (Phase 3)Active Not RecruitingNCT06760637What this trial is testingStudy of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic DiseaseWho this might be right forBreast Cancer Pfizer 1,035
Testing effectiveness (Phase 2)Study completedNCT01565200What this trial is testingHER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1Who this might be right forHER-2 Positive Breast Cancer Jules Bordet Institute 90
Testing effectiveness (Phase 2)Study completedNCT02614794What this trial is testingTucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast CancerWho this might be right forHER2 Positive Breast Cancer Seagen Inc. 612
Early research (Phase 1)Ended earlyNCT07214662What this trial is testingEvaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast CancerWho this might be right forBreast Cancer Genentech, Inc. 3
Testing effectiveness (Phase 2)UnknownNCT03202862What this trial is testingThe Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast CancerWho this might be right forBreast Neoplasms Fudan University 50
Testing effectiveness (Phase 2)UnknownNCT05429294What this trial is testingNovel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038Who this might be right forHER2-positive Breast Cancer First Affiliated Hospital Xi'an Jiaotong University 209
Large-scale testing (Phase 3)UnknownNCT03927456What this trial is testingSHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast CancerWho this might be right forAdvanced Breast Cancer Jiangsu HengRui Medicine Co., Ltd. 357
Testing effectiveness (Phase 2)UnknownNCT05420779What this trial is testingEvaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA MutationsWho this might be right forBreast Cancer Metastatic Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. 125
Early research (Phase 1)Ended earlyNCT03294694What this trial is testingRibociclib + PDR001 in Breast Cancer and Ovarian CancerWho this might be right forMetastatic Hormone-Receptor-Positive (HR+) Breast CancerHER2-Negative Breast CancerMetastatic Epithelial Ovarian Cancer Dana-Farber Cancer Institute 33
Post-approval studies (Phase 4)Study completedNCT04707196What this trial is testingAbemaciclib in Indian Women With Advanced Breast CancerWho this might be right forBreast NeoplasmsNeoplasm Metastasis Eli Lilly and Company 200
Large-scale testing (Phase 3)Active Not RecruitingNCT05132582What this trial is testingTucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerWho this might be right forHER2 Positive Breast Cancer Seagen, a wholly owned subsidiary of Pfizer 654